SCD, MCI, Early Dementia and AD
Delphi-MD enables the early diagnosis of Dementia . Fogel et al; Dementia and Neurodegeneration.
StrokeTBI
Delphi-MD detects white matter changes. Levy-Lamdan et al; Frontiers in Aging Neuroscience.
Parkinson’s Disease
Delphi and Aging
White Matter Pathologies
Events
Upcoming Events:
HLTH, Oct. 08-11, 2023
Save the date – Come and experience Delphi-MD at HLTH 2023 in las Vegas.
MEDICA, Nov.13-16, 2023
Save the date – Come and experience Delphi-MD at Medica 23 in Dusseldorf.
Previous Events:
White Papers
Review of Neurodiagnostic Technologies
As the world’s population ages, the prevalence of neurological disorders and the need for preserving brain health are on the rise.
Press Coverage
QuantalX Receives FDA Breakthrough Designation for Diagnosis of Normal Pressure Hydrocephalus and Prediction of Treatment Response
The FDA grants the Delphi-MD device breakthrough designation technology status for the diagnosis of Normal Pressure Hydrocephalus (NPH) patients and prediction of response to highly effective, ventriculoperitoneal shunting surgery (VPS) treatment. KFAR SABA, Israel,...
NeuroSense and QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative Diseases
QuantalX's direct electrophysiology imaging technology (Delphi-MD) expected to provide multiple clinically objective and accurate measurements in NeuroSense's Phase 2 double-blind proof-of-concept clinical study in Alzheimer's disease, expected to commence in H1 2023...
Delphi-MD Breakthrough diagnostic technology promises to reduce healthcare burden by detecting brain abnormalities prior to symptoms, at the point of care
Delphi-MD, World's first direct brain network visualization technology showcasing at the HLTH Las Vegas conference today, provides objective clinical measurements of neuronal functions for the first time, enabling point of care physicians and neurologists access to...
Amyotrophic Lateral Sclerosis Pipeline Booms as 100+ Therapies Likely to Enter in the Treatment Domain | DelveInsight
The prevalence of amyotrophic lateral sclerosis has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of amyotrophic lateral sclerosis and the growing research and development activities to develop novel therapies to treat amyotrophic lateral sclerosis to drive the market. The companies developing the potential therapies in the last stage of development include Biogen, AB Sciences, Helixmith, and several others.
Want to Join the Brain Health Revolution?
